Form 8-K - Current report:
SEC Accession No. 0001213900-25-030129
Filing Date
2025-04-09
Accepted
2025-04-09 10:13:49
Documents
15
Period of Report
2025-04-03
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0237701-8k_inmune.htm   iXBRL 8-K 25049
2 POSTER PRESENTATION ea023770101ex99-1_inmune.htm EX-99.1 8224
3 GRAPHIC ex99-1_001.jpg GRAPHIC 431046
  Complete submission text file 0001213900-25-030129.txt   804684

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE inmb-20250403.xsd EX-101.SCH 3008
5 XBRL LABEL FILE inmb-20250403_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE inmb-20250403_pre.xml EX-101.PRE 22354
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0237701-8k_inmune_htm.xml XML 3679
Mailing Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432
Business Address 225 NE MIZNER BLVD, SUITE 640 BOCA RATON FL 33432 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 25824126
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)